NO994431L - Ny formulering - Google Patents

Ny formulering

Info

Publication number
NO994431L
NO994431L NO994431A NO994431A NO994431L NO 994431 L NO994431 L NO 994431L NO 994431 A NO994431 A NO 994431A NO 994431 A NO994431 A NO 994431A NO 994431 L NO994431 L NO 994431L
Authority
NO
Norway
Prior art keywords
wording
new
new wording
formulation
balsazide
Prior art date
Application number
NO994431A
Other languages
English (en)
Other versions
NO994431D0 (no
Inventor
Stefan Friess
Harald Heckenmueller
Oliver Szambien
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20406161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994431(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO994431L publication Critical patent/NO994431L/no
Publication of NO994431D0 publication Critical patent/NO994431D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Enhetsformulering som omfatter et 2-hydroksy-5-fenylazobenzosyrederivat som spesielt er natriumbalsaziddihydrat, hvilken formulering har en densitet på minst 0,9 mg/mm' og dens anvendelse i behandlingen av gastrointestinale sykdommer.
NO994431A 1997-03-14 1999-09-13 Ny formulering NO994431D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700934A SE9700934D0 (sv) 1997-03-14 1997-03-14 New formulation
PCT/SE1998/000455 WO1998041212A1 (en) 1997-03-14 1998-03-13 New formulation

Publications (2)

Publication Number Publication Date
NO994431L true NO994431L (no) 1999-09-13
NO994431D0 NO994431D0 (no) 1999-09-13

Family

ID=20406161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994431A NO994431D0 (no) 1997-03-14 1999-09-13 Ny formulering

Country Status (15)

Country Link
US (1) US6197341B1 (no)
EP (1) EP1003524A1 (no)
JP (1) JP2001519782A (no)
AU (1) AU6430198A (no)
BE (1) BE1011837A5 (no)
BR (1) BR9808140A (no)
CA (1) CA2283297A1 (no)
FR (1) FR2760638A1 (no)
GR (1) GR980100096A (no)
HU (1) HUP0000850A3 (no)
NL (1) NL1008575C2 (no)
NO (1) NO994431D0 (no)
PL (1) PL335700A1 (no)
SE (1) SE9700934D0 (no)
WO (1) WO1998041212A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
AU2001285489A1 (en) * 2000-08-29 2002-03-13 Nobex Corporation 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
PT1642885E (pt) 2000-08-29 2009-12-17 Biocon Ltd Utilização de uma composição farmacêutica contendo um derviado de ácido para-aminofenilacético para o tratamento de estados inflamatórios do tracto gastrointestinal
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
PL2361620T3 (pl) 2004-02-06 2016-12-30 Zastosowanie aminosalicylanów w zespole jelita drażliwego z dominującą postacią biegunkową
ATE472999T1 (de) * 2004-05-28 2010-07-15 Salix Pharmaceuticals Inc Prävention, behandlung und linderung strahlungsinduzierter enteritis
DE602005022175D1 (de) * 2004-05-28 2010-08-19 Salix Pharmaceuticals Inc Prävention, behandlung und linderung strahlungsinduzierter enteritis
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
KR20090021346A (ko) * 2006-06-06 2009-03-03 안티브 테라퓨틱스 인크. 트리메부틴 및 ｎ-데스메틸 트리메부틴 염
MX358142B (es) 2010-04-26 2018-08-06 Salix Pharmaceuticals Ltd Formulaciones y usos del derivado del ácido 2 - hidroxi -5 - fenilazobenzóico para el tratamiento de varones.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045429A (en) 1970-03-06 1977-08-30 Pharmacia Aktiebolag 4-(4-Hydroxy- or acetoxy-3-carbomethoxyphenylazo)-benzenesulphonyl chloride
BE791889A (fr) 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
JPS57500432A (no) * 1980-03-20 1982-03-11
GB2080796B (en) * 1980-07-21 1983-10-12 Biorex Laboratories Ltd 2-hydroxy-5-phenylazobenzoic acid derivatives
US4412992A (en) 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation

Also Published As

Publication number Publication date
NL1008575C2 (nl) 1999-09-10
EP1003524A1 (en) 2000-05-31
AU6430198A (en) 1998-10-12
BR9808140A (pt) 2000-03-28
PL335700A1 (en) 2000-05-08
FR2760638A1 (fr) 1998-09-18
WO1998041212A1 (en) 1998-09-24
NL1008575A1 (nl) 1998-09-15
NO994431D0 (no) 1999-09-13
CA2283297A1 (en) 1998-09-24
HUP0000850A3 (en) 2000-10-30
BE1011837A5 (fr) 2000-02-01
HUP0000850A2 (hu) 2000-09-28
US6197341B1 (en) 2001-03-06
GR980100096A (el) 1998-11-30
JP2001519782A (ja) 2001-10-23
SE9700934D0 (sv) 1997-03-14

Similar Documents

Publication Publication Date Title
NO994431L (no) Ny formulering
DE69905368D1 (en) Oxydiertes thymosin beta 4
DK0693281T3 (da) Farmaceutiske fluoxetinformuleringer
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
EE05260B1 (et) Metformiini ja glburiidi kombinatsiooni v„ikese annuse kasutamine 2. tpi suhkrut?ve esimese rea raviks
BR9809185A (pt) Diidropiranos fundidos
PT998287E (pt) Utilizacao de levobupivacaina
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
NO870772L (no) Vevplasminogenaktivator for normale humane tykktarmceller.
SE9700885D0 (sv) New pharmaceutical formulation
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
EE9900450A (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
ES2149691A1 (es) 2-4-[4-(4,5-dicloro-2metilimidazol-1-il)butil]-1-piperacinil -5-fluoropirimidina, su preparacion y su utilizacion terapeutica.
DK1007047T3 (da) Anvendelse af mizolastin til fremstilling af et lægemiddel beregnet til inflammationsbehandling